Sorrento Therapeutics, Inc. (SRNE)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2022 | 104.33 Million USD | -46.23% |
| 2021 | 194.05 Million USD | 36.12% |
| 2020 | 142.55 Million USD | -43.25% |
| 2019 | 251.19 Million USD | 12.58% |
| 2018 | 223.13 Million USD | 4182.02% |
| 2017 | 5.21 Million USD | -88.94% |
| 2016 | 47.1 Million USD | 972.08% |
| 2015 | 4.39 Million USD | -50.24% |
| 2014 | 8.83 Million USD | 99.28% |
| 2013 | 4.43 Million USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q1 | 105.86 Million USD | 1.46% |
| 2023 Q2 | 74.18 Million USD | -29.92% |
| 2022 Q4 | 104.33 Million USD | 2.36% |
| 2022 Q1 | 179.49 Million USD | 62.25% |
| 2022 FY | 104.33 Million USD | -46.23% |
| 2022 Q3 | 101.93 Million USD | -39.1% |
| 2022 Q2 | 167.38 Million USD | -6.74% |
| 2021 Q4 | 110.62 Million USD | 32.5% |
| 2021 Q1 | 129.31 Million USD | -9.29% |
| 2021 Q2 | 130.96 Million USD | 1.28% |
| 2021 Q3 | 83.49 Million USD | -36.24% |
| 2021 FY | 194.05 Million USD | 36.12% |
| 2020 Q4 | 142.55 Million USD | -28.97% |
| 2020 Q3 | 200.69 Million USD | 1.25% |
| 2020 Q2 | 198.22 Million USD | -15.67% |
| 2020 Q1 | 235.05 Million USD | -6.43% |
| 2020 FY | 142.55 Million USD | -43.25% |
| 2019 FY | 251.19 Million USD | 12.58% |
| 2019 Q2 | 275.63 Million USD | -0.6% |
| 2019 Q4 | 251.19 Million USD | -12.7% |
| 2019 Q1 | 277.29 Million USD | 24.27% |
| 2019 Q3 | 287.74 Million USD | 4.4% |
| 2018 Q2 | 16.2 Million USD | 194.55% |
| 2018 Q4 | 223.13 Million USD | 53.32% |
| 2018 FY | 223.13 Million USD | 4182.02% |
| 2018 Q1 | 5.5 Million USD | 5.57% |
| 2018 Q3 | 145.53 Million USD | 798.2% |
| 2017 FY | 5.21 Million USD | -88.94% |
| 2017 Q1 | 26.08 Million USD | -44.63% |
| 2017 Q2 | 26.54 Million USD | 1.76% |
| 2017 Q3 | 24.57 Million USD | -7.41% |
| 2017 Q4 | 5.21 Million USD | -78.8% |
| 2016 FY | 47.1 Million USD | 972.08% |
| 2016 Q1 | 3.11 Million USD | -29.15% |
| 2016 Q2 | 1.8 Million USD | -42.15% |
| 2016 Q3 | 458 Thousand USD | -74.57% |
| 2016 Q4 | 47.1 Million USD | 10185.37% |
| 2015 FY | 4.39 Million USD | -50.24% |
| 2015 Q2 | 6.86 Million USD | -10.29% |
| 2015 Q1 | 7.65 Million USD | -13.3% |
| 2015 Q3 | 5.64 Million USD | -17.79% |
| 2015 Q4 | 4.39 Million USD | -22.17% |
| 2014 Q2 | 9.44 Million USD | -8.48% |
| 2014 Q3 | 8.44 Million USD | -10.55% |
| 2014 FY | 8.83 Million USD | 99.28% |
| 2014 Q4 | 8.83 Million USD | 4.55% |
| 2014 Q1 | 10.31 Million USD | 132.84% |
| 2013 Q4 | 4.43 Million USD | -7.41% |
| 2013 FY | 4.43 Million USD | 0.0% |
| 2013 Q2 | 535.26 Thousand USD | -12.0% |
| 2013 Q1 | 608.25 Thousand USD | 0.0% |
| 2013 Q3 | 4.78 Million USD | 794.01% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| America Great Health | 1.12 Million USD | -9189.865% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | 1.29 Million USD | -7975.697% |
| Biora Therapeutics, Inc. | 43.73 Million USD | -138.563% |
| Bio-Path Holdings, Inc. | 10 Thousand USD | -1043280.0% |
| Better Therapeutics, Inc. | 10.34 Million USD | -908.291% |
| Calithera Biosciences, Inc. | 136 Thousand USD | -76619.118% |
| Comera Life Sciences Holdings, Inc. | 120.3 Thousand USD | -86630.063% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | - USD | -Infinity% |
| Eloxx Pharmaceuticals, Inc. | 8.69 Million USD | -1100.391% |
| Evelo Biosciences, Inc. | 48.87 Million USD | -113.462% |
| Evolutionary Genomics, Inc. | 3.74 Million USD | -2686.994% |
| Finch Therapeutics Group, Inc. | 28.4 Million USD | -267.349% |
| Galera Therapeutics, Inc. | 151.04 Million USD | 30.924% |
| Innovation1 Biotech Inc. | 218.99 Thousand USD | -47543.14% |
| Kiromic BioPharma, Inc. | 911.5 Thousand USD | -11346.846% |
| Molecular Templates, Inc. | 9.74 Million USD | -971.012% |
| Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | -5474.46% |
| NexImmune, Inc. | - USD | -Infinity% |
| Orgenesis Inc. | 19.06 Million USD | -447.218% |
| Panbela Therapeutics, Inc. | 4.19 Million USD | -2387.792% |
| Point of Care Nano-Technology, Inc. | - USD | -Infinity% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| Statera Biopharma, Inc. | 11.43 Million USD | -812.752% |
| TRACON Pharmaceuticals, Inc. | 732 Thousand USD | -14153.825% |
| Trevena, Inc. | 35.23 Million USD | -196.137% |
| Vaxxinity, Inc. | 13.26 Million USD | -686.744% |
| Vaccinex, Inc. | 26 Thousand USD | -401200.0% |
| Vicapsys Life Sciences, Inc. | - USD | -Infinity% |
| Viracta Therapeutics, Inc. | - USD | -Infinity% |
| ZIVO Bioscience, Inc. | - USD | -Infinity% |